Docket No. JBP0438

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Miri Seiberg et al. Confirmation No.: 5255

Serial No.: 09/206,249 Art Unit: 1654

Filed : December 7, 1998 Examiner: Michael V. Meller

For : Compositions and Methods for Regulating

Phagocytosis and ICAM-1 Expression

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 22, 2005
(Date of Deposit)

Andrea L. Colby, Reg. No. 30,194
(Name of applicant, assignee, or Registered Representative)

/Andrea L. Colby/
(Signature)

April 22, 2005
(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on March 25, 2005.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

In accordance with §1.129(a), this Information

П

accompanied by one of:

<b>—</b>
Disclosure Statement is being filed in connection with $\square$ the
first or _second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
☐ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is

•	<pre>Statement in Accordance with §1.97(e)</pre>
	(attached); or
	☐ Please charge Deposit Account No. 10-
	0750/ / the fee of $$180.00$ as set forth
	in §1.17(p).
	To assert the St. Off(d) this Information
	In accordance with §1.97(d), this Information
	Disclosure Statement is being filed after the mailing date of
	either a Final Action under §1.113 or a Notice of Allowance
	under §1.311 but before the payment of the Issue Fee.
	Applicant(s) hereby petition(s) for consideration of this
	Information Disclosure Statement. Included are: Statement in
	Accordance with §1.97(e) as set forth below and the fee of
	\$180.00 as set forth in §1.17(p).
	☐ Copies of each of the references listed on the
	attached Form PTO-1449 are enclosed herewith.
	attached Form F10-1449 are enclosed herewith.
	Copies of only foreign patent documents and non-
	patent literature are enclosed in accordance with 37 CFR 1.98
	(a)(2). (The U.S. patents and each U.S. patent application
	publication listed on the attached Form PTO-1449 are not
	enclosed because this U.S. patent application was filed after
	June 30, 2003 or this international application has entered the
	national stage under 35 USC §371 after June 30, 2003 (see USPTO
	waiver of requirement under 37 CFR 1.98 (a)(2)(i).
	$oxed{oxed}$ There are no listed references which are not in the
	English language.
	The relevance of those listed references which are
	not in the English language is as follows: .

Attached are copies of search report(s) from					
corresponding patent application(s), which are listed on the					
attached Submission Under MPEP 609 D.					
Attached are the following non-published pending					
patent applications which may be deemed relevant, which are					
listed on the attached Submission Under MPEP 609 D.					

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JBP0438/ALC. This form is submitted in triplicate.

Respectfully submitted,

/Andrea L. Colby/ Andrea L. Colby Reg. No. 30,194 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2793 DATED: April 22, 2005 APR 2 2 2005

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control numb

INFORMATION	DISCL	<b>OSURE</b>
STATEMENT B	Y APP	LICANT

1449A/PTO

(use as many sheets as necessary)
Sheet 1 of 1

C	to respond to a collection of information unles	ss it displays a valid Owlb condoi number.
	Confirmation Number	5255
	Application Number	09/206,249
	Filing Date	12/07/1998
	First Named Inventor	Miri Seiberg
	Group Art Unit	1654
İ	Examiner Name	Michael V. Meller
	Attorney Docket Number	JBP438

				U.S. PATENT DOCUMENTS			
		U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,	
Exam Initials	Cite No. <sup>1</sup>	Number (if known)		of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear	
		6,399,083	B1	Pillai et al.	06-04-2002		
			<u> </u>				
			ļ				
-							
				FOREIGN DATENT DOCUMENTS			
	T	Foreign Patent Document		FOREIGN PATENT DOCUMENTS	Date of	Pages, Columns,	
Exam Initials	Cite No.1	Office <sup>3</sup> Number <sup>4</sup> Kindo	Code <sup>5</sup>	Name of Patentee or Applicant of Cited Document		Lines, where relevant passages or relevant figures appear	T⁵
	140.						
						-	
	<del></del>			ART - NON PATENT LITERATURE DO			
Exam Initials	Cite No.1	Include name of the au	thor (in CAF	PITAL LETTERS), title of the article (when applic), date, page(s), volume-issue number(s), p	propriate), title of the item	n (book, magazine, ntry where published	T²
	1						

Examiner Date Signature Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.